title: Ranolazine Therapy in Cardiac Arrhythmias.
abstract: Ranolazine is an antianginal medication originally granted approval by the U.S. Food and Drug Administration for therapeutic use in 2006. Since its introduction into the U.S. market, there have been multiple trials and clinical case reports that demonstrate ranolazine may be effective in the prevention and treatment of both atrial and ventricular arrhythmias, including postoperative atrial fibrillation following coronary artery bypass graft (CABG) surgery. More recently, the combination of dronedarone with ranolazine has demonstrated in initial studies to have a synergistic effect in the reduction of burden of atrial fibrillation. This article will review the basic pharmacology of ranolazine, the studies demonstrating use of ranolazine in atrial and ventricular arrhythmias, the limitations to the use of ranolazine as antiarrhythmic therapy, and explore the synergistic effect with other agents in the suppression of arrhythmias.
authors.affiliation: Department of Medicine, University of Connecticut School of Medicine. bpulford@uchc.edu.
authors.forename: Brian R
authors.initials: BR
authors.lastname: Pulford
authors.affiliation: Department of Cardiology, Hartford Hospital.
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Kluger
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects; D001145:Arrhythmias, Cardiac / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D006801:Humans; D000069458:Ranolazine / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000889:Anti-Arrhythmia Agents; D000069458:Ranolazine
keywords: VT; atrial fibrillation; clinical trials; data analysis; pharmacology